email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2637-6679

Research and Reviews on Healthcare: Open Access Journal

Letter to Editor(ISSN: 2637-6679)

Prevention of Anti-BRAF-Induced Phototoxicity: not Just a Question of Photoprotector

Volume 3 - Issue 5

M Cormerais1, A Boisrobert2, H Dutartre2, A Khammari2 and B Dreno2*

  • Author Information Open or Close
    • 1Service de Dermatologie, CHU Pontchaillou, France
    • 2Service de Dermatologie, CHU de Nantes, France

    *Corresponding author:B Dreno, Service de Dermatologie, CHU de Nantes, Place Alexis Ricordeau 44093 Nantes, France

Received:July 09, 2019;   Published:July 17, 2019;

DOI: 10.32474/RRHOAJ.2019.03.000171

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Targeted therapies changed the prognosis of metastatic melanoma. Flaherty & al. and the BRIM-II study found a response rate between 53-81% and a median progression-free survival of about seven months [1,2]. The BRIM-III study reported a median survival of 13.6 months and a 6-month survival rate of 84% with Vemurafenib versus 9.7 months and 64% with dacarbazine [3]. The UVA-phototoxicity induced by Vemurafenib through a decrease in minimal erythema dose

Letter to Editor| Acknowledgment| References|